The role of serum and urinary carbohydrate antigen 19-9 in predicting renal injury associated with ureteral stone

Figures & data

Figure 1. Scatter plots show the correlation between serum (A) and urinary (B) carbohydrate antigen 19-9 concentration and duration of obstruction in patients with ureteral stone.

Figure 2. Box plots show the difference in serum (A) and urinary (B) carbohydrate antigen 19-9 concentration in patients with ureteral obstruction lasting <14 days compared to >14 days.

Table 1. Serum and urinary carbohydrate antigen 19-9 levels in study groups (values are shown in median [interquartile range]).

	Serum CA19-9(KU/L)	UrinaryCA19-9 (KU/L)
Group A
Baseline	15.0 [8.4–26.3]	34 [15.7–72.6]
4 weeks after transurethral lithotripsy	4.7 [2.7–9.2]	13.4 [11.0–20.5]
8 weeks after transurethral lithotripsy	4.5 [3.4–6.9]	12.5 [11.2–15.8]
Group B (control)	5.3 [1.5–12.2]	16.1 [9.3–27.5]

Figure 3. Receiver operating characteristic curve analysis of serum and urinary carbohydrate antigen 19-9 for detecting obstructive hydronephrosis in patients with ureteral stone.